(a).
| Serious adverse events | Placebo (n = 20) | ASC (n = 40) | P value |
|---|---|---|---|
| Death | 0 (0) | 1 (2.5) | 1.00 |
| Hospitalizations | |||
| Myocardial infarction | 1 (5) | 1 (2.5) | 1.00 |
| Dyspnea | 0 (0) | 1 (2.5) | 1.00 |
| Anemia | 1 (5) | 1 (2.5) | 1.00 |
| Syncope | 1 (5) | 0 (0) | 0.33 |
| Peripheral edema | 0 (0) | 1 (2.5) | 1.00 |
| Angina worsening | 3 (15) | 6 (15) | 1.00 |
| Pneumonia | 1 (5) | 1 (2.5) | 1.00 |
| NOGA-related complications | |||
| Pericardial effusion | 0 (0) | 1 (2.5) | 1.00 |
| ECG changes—SA-block, NsVT | 2 (10) | 1 (2.5) | 0.26 |
| Hematoma at femoral puncture | 1 (5) | 0 (0) | 0.33 |
| Allergic reaction | 0 (0) | 1 (2.5) | 1.00 |
| Bradycardia | 0 (0) | 1 (2.5) | 1.00 |
| General discomfort | 0 (0) | 1 (2.5) | 1.00 |
NsVT: nonsustained ventricular tachycardia; SA-block: sinoatrial block. Values are n (%); P values are calculated using Fischer's exact test.